Insider · CIK 0001622769
Isaac Manke
director
Files at ADXN (Addex Therapeutics Ltd.), OKUR (OnKure Therapeutics, Inc.), QTTB (Q32 Bio Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Common Stock | -219,561 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Common Stock | +219,561 | $0.00 | $0 | 219,561 | 38 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | DDisposition to issuer Stock-option (Right to Buy)derivative | -50,000 | $0.00 | $0 | 0 | 38 d ago |
| Sep 2, 2026 | ADXN Addex Therapeutics Ltd. | AGrant or award Stock-option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | 38 d ago |
| Oct 23, 2025 | QTTB Q32 Bio Inc. | AGrant or award Stock Option (Right to Buy)derivative | +53,521 | $0.00 | $0 | 53,521 | Oct 27, 2025 |
| Sep 30, 2025 | OKUR OnKure Therapeutics, Inc. | AGrant or award Class A Common Stock | +5,545 | $0.00 | $0 | 15,325 | Oct 2, 2025 |
| Jun 30, 2025 | OKUR OnKure Therapeutics, Inc. | AGrant or award Class A Common Stock | +6,311 | $0.00 | $0 | 9,780 | Jul 2, 2025 |
| May 28, 2025 | OKUR OnKure Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +7,650 | $0.00 | $0 | 7,650 | May 30, 2025 |
| Mar 31, 2025 | OKUR OnKure Therapeutics, Inc. | AGrant or award Class A Common Stock | +3,469 | $0.00 | $0 | 3,469 | Apr 2, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.